Vanda Pharmaceuticals Inc

VNDA

7.570USD

+0.340+4.70%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Vanda Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

48 / 392

Overall Ranking

155 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Vanda Pharmaceuticals Inc Highlights

StrengthsRisks

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -5.29, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 45.94M shares, decreasing 18.41% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 25.91K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

13.625

Target Price

+79.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Vanda Pharmaceuticals Inc is 8.22, ranking 55 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 56.26M, representing a year-over-year increase of 18.06%, while its net profit experienced a year-over-year increase of 324.23%.

Score

Industry at a Glance

Previous score

8.22

Change

0



Financials

7.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.37

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.36

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Vanda Pharmaceuticals Inc is 8.84, ranking 12 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.29, which is -2092.81% below the recent high of 105.42 and -1344.04% above the recent low of -76.39.

Score

Industry at a Glance

Previous score

8.84

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 48/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Vanda Pharmaceuticals Inc is 7.50, ranking 284 out of 392 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.50

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Vanda Pharmaceuticals Inc is 7.08, ranking 107 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.21 and the support level at 7.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.58

Change

0.5

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Vanda Pharmaceuticals Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 77.74%, representing a quarter-over-quarter decrease of 1.09%. The largest institutional shareholder is The Vanguard, holding a total of 3.70M shares, representing 6.26% of shares outstanding, with 5.60% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.77M

-3.54%

The Vanguard Group, Inc.

Star Investors

3.56M

+0.40%

Renaissance Technologies LLC

Star Investors

3.48M

+0.85%

Dimensional Fund Advisors, L.P.

2.56M

-0.84%

Tang Capital Management, LLC

2.35M

--

Polymeropoulos (Mihael Hristos)

2.34M

+0.43%

BlackRock Financial Management, Inc.

2.25M

-7.66%

Acadian Asset Management LLC

2.23M

+28.69%

Millennium Management LLC

3.25M

+4.18%

Two Sigma Investments, LP

1.57M

+17.63%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vanda Pharmaceuticals Inc is 3.75, ranking 122 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Vanda Pharmaceuticals Inc

VNDA

7.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment